Corcept Therapeutics Incorporat - stock earnings
CORT Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 1, 2024 AfterMarket | - / 0.2244000000 | - | - / 144.0 million | - |
CORT Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | 31.4 million USD | 135.4 million USD |
| 2023Q3 | 31.4 million USD | 123.6 million USD |
| 2023Q2 | 27.5 million USD | 117.7 million USD |
| 2023Q1 | 15.9 million USD | 105.7 million USD |
| 2022Q4 | 16.6 million USD | 103.1 million USD |
| 2022Q3 | 34.6 million USD | 101.7 million USD |
| 2022Q2 | 27.4 million USD | 103.4 million USD |
| 2022Q1 | 22.8 million USD | 93.7 million USD |
| 2021Q4 | 32.1 million USD | 98.8 million USD |
| 2021Q3 | 30.5 million USD | 96.1 million USD |
| 2021Q2 | 26.5 million USD | 91.6 million USD |
| 2021Q1 | 23.5 million USD | 79.4 million USD |
| 2020Q4 | 26.0 million USD | 85.7 million USD |
| 2020Q3 | 21.6 million USD | 86.3 million USD |
| 2020Q2 | 28.3 million USD | 88.6 million USD |
| 2020Q1 | 30.1 million USD | 93.2 million USD |
| 2019Q4 | 29.4 million USD | 87.9 million USD |
| 2019Q3 | 26.3 million USD | 81.5 million USD |
| 2019Q2 | 20.2 million USD | 72.3 million USD |
| 2019Q1 | 18.3 million USD | 64.8 million USD |
| 2018Q4 | 22.0 million USD | 66.8 million USD |
| 2018Q3 | 17.7 million USD | 64.4 million USD |
| 2018Q2 | 18.2 million USD | 62.3 million USD |
| 2018Q1 | 17.5 million USD | 57.7 million USD |
| 2017Q4 | 98.3 million USD | 53.3 million USD |
| 2017Q3 | 13.8 million USD | 42.8 million USD |
| 2017Q2 | 12.6 million USD | 35.6 million USD |
| 2017Q1 | 4.4 million USD | 27.6 million USD |
| 2016Q4 | 4.6 million USD | 23.8 million USD |
| 2016Q3 | 2.6 million USD | 21.7 million USD |
| 2016Q2 | 977000 USD | 19.7 million USD |
| 2016Q1 | -19000 USD | 16.1 million USD |
| 2015Q4 | 959000 USD | 15.0 million USD |
| 2015Q3 | -601000 USD | 13.3 million USD |
| 2015Q2 | -1.9 million USD | 12.0 million USD |
| 2015Q1 | -4.8 million USD | 10.1 million USD |
| 2014Q4 | -3.9 million USD | 9.0 million USD |
| 2014Q3 | -6.0 million USD | 7.3 million USD |
| 2014Q2 | -7.6 million USD | 5.9 million USD |
| 2014Q1 | -13.9 million USD | 4.4 million USD |
| 2013Q4 | -11.1 million USD | 4.1 million USD |
| 2013Q3 | -10.9 million USD | 2.6 million USD |
| 2013Q2 | -11.9 million USD | 1.9 million USD |
| 2013Q1 | -12.1 million USD | 1.7 million USD |
| 2012Q4 | -11.1 million USD | 1.4 million USD |
| 2012Q3 | -8.3 million USD | 1.1 million USD |
| 2012Q2 | -7.6 million USD | 875000 USD |
| 2012Q1 | -11.0 million USD | ? USD |
| 2011Q4 | -9.9 million USD | ? USD |
| 2011Q3 | -6.4 million USD | ? USD |
| 2011Q2 | -8.9 million USD | ? USD |
| 2011Q1 | -7.1 million USD | ? USD |
| 2010Q4 | -7.1 million USD | ? USD |
| 2010Q3 | -7.1 million USD | ? USD |
| 2010Q2 | -5.7 million USD | ? USD |
| 2010Q1 | -6.1 million USD | ? USD |
| 2009Q4 | -5.2 million USD | -1000 USD |
| 2009Q3 | -4.7 million USD | 1.0 million USD |
| 2009Q2 | -4.9 million USD | 6000 USD |
| 2009Q1 | -5.5 million USD | 24000 USD |
| 2008Q4 | -6.2 million USD | 143000 USD |
| 2008Q3 | -5.6 million USD | 66000 USD |
| 2008Q2 | -4.4 million USD | ? USD |
| 2008Q1 | -3.9 million USD | ? USD |
| 2007Q4 | -4.2 million USD | 482000 USD |
| 2007Q3 | -3.4 million USD | 374000 USD |
| 2007Q2 | -1.4 million USD | 374000 USD |
| 2007Q1 | -3.9 million USD | 73000 USD |
| 2006Q4 | -3.9 million USD | 73000 USD |
| 2006Q3 | -6.4 million USD | 100000 USD |
| 2006Q2 | -7.9 million USD | 100000 USD |
| 2006Q1 | -6.7 million USD | 121000 USD |
| 2005Q4 | -5.2 million USD | ? USD |
| 2005Q3 | -5.2 million USD | ? USD |
| 2005Q2 | -4.1 million USD | ? USD |
| 2005Q1 | -5.5 million USD | ? USD |
| 2004Q4 | -5.3 million USD | ? USD |
| 2004Q3 | -4.1 million USD | ? USD |
| 2004Q2 | -3.6 million USD | ? USD |
| 2004Q1 | -2.6 million USD | ? USD |
| 2003Q4 | -2.0 million USD | ? USD |
| 2003Q3 | -2.1 million USD | ? USD |
| 2003Q2 | -2.9 million USD | ? USD |
| 2003Q1 | -2.8 million USD | ? USD |
CORT Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | 106.1 million USD | 482.4 million USD |
| 2022 | 101.4 million USD | 401.9 million USD |
| 2021 | 112.5 million USD | 366.0 million USD |
| 2020 | 106.0 million USD | 353.9 million USD |
| 2019 | 94.2 million USD | 306.5 million USD |
| 2018 | 75.4 million USD | 251.2 million USD |
| 2017 | 129.1 million USD | 159.2 million USD |
| 2016 | 8.1 million USD | 81.3 million USD |
| 2015 | -6.4 million USD | 50.3 million USD |
| 2014 | -31.4 million USD | 26.6 million USD |
| 2013 | -46.0 million USD | 10.4 million USD |
| 2012 | -38.0 million USD | 3.3 million USD |
| 2011 | -32.4 million USD | ? USD |
| 2010 | -26.0 million USD | ? USD |
| 2009 | -20.2 million USD | 29000 USD |
| 2008 | -20.1 million USD | 209000 USD |
| 2007 | -11.6 million USD | 482000 USD |
| 2006 | -24.9 million USD | 294000 USD |
| 2005 | -20.1 million USD | ? USD |
| 2004 | -15.5 million USD | ? USD |
| 2003 | -9.8 million USD | ? USD |
| 2002 | -18.5 million USD | ? USD |
| 2001 | -7.5 million USD | ? USD |
CORT
Price: $23.37
52 week price:
Payout Ratio Range:
Earnings Per Share: 0.94 USD
P/E Ratio: 28.76
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 611800
Ebitda: 13.7 millionMarket Capitalization: 2.6 billion